Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 131Squamous Cell Carcinoma of Head and Neck 75Lung Neoplasms 47Head and Neck Neoplasms 45Urinary Bladder Neoplasms 43Parkinson Disease 4, Autosomal Dominant Lewy Body 33Oropharyngeal Neoplasms 32Nasopharyngeal Carcinoma 31Biliary Tract Neoplasms 31Uterine Cervical Neoplasms 29Cholangiocarcinoma 28Esophageal Squamous Cell Carcinoma 24Neoplasms 23Carcinoma 23Neoplasm Metastasis 22Small Cell Lung Carcinoma 21Ovarian Neoplasms 21Carcinoma, Squamous Cell 20Stomach Neoplasms 18Colorectal Neoplasms 18Carcinoma, Transitional Cell 17Pancreatic Neoplasms 16Esophageal Neoplasms 16Mesothelioma, Malignant 15Gallbladder Neoplasms 15Mouth Neoplasms 14Laryngeal Neoplasms 13Hypopharyngeal Neoplasms 12Endometrial Neoplasms 11Triple Negative Breast Neoplasms 10

Interventions

Vincristine 1Radiotherapy 1Pemetrexed 1HhAntag691 1Gemcitabine 1Exercise 1Cyclophosphamide 1Craniospinal Irradiation 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Infratentorial Neoplasms × Cisplatin × 1 year × Clear all
NCT01878617 2025-11-13

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
660 enrolled
CNS

Brain Neoplasms, Medulloblastoma, Infratentorial Neoplasms, Neuroectodermal Tumors, Primitive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡